Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05269290
Other study ID # ING-03-04-2020
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 23, 2021
Est. completion date July 15, 2022

Study information

Verified date July 2023
Source Valenta Pharm JSC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date July 15, 2022
Est. primary completion date April 29, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months to 2 Years
Eligibility Inclusion Criteria: 1. Patient's parent/adoptive parent's informed consent form voluntarily signed by the patient's parent/adoptive parent; 2. Boys and girls aged 6 months - 2 years 11 months 14 days, inclusive, with the following clinical signs of acute respiratory infections/flu: body temperature above 38.0 °C but not higher than 39.0 °C (without taking antipyretics within the last 8 h) at the time of screening/randomization; at least one of the respiratory manifestations of acute respiratory infection/influenza (cough, runny nose/ stuffy nose) of at least 2 points on a 4-point scale; decrease in the child's daytime activity and change in nighttime sleep, as compared with the state before the illness; 3. There were no indications for hospitalization at the time of inclusion in the study; 4. Duration of illness from manifestation of symptoms to inclusion in the study not more than 48 hours. Exclusion Criteria: 1. Presence of at least one of the epidemic signs: return from an overseas trip 14 days prior to the onset of symptoms; having close contact in the last 14 days with a person under observation for COVID-19 who has subsequently become ill; having close contact within the past 14 days with a person who has a laboratory-confirmed diagnosis of COVID-19; 2. Positive result of laboratory testing for SARS-CoV-2 RNA using nucleic acid amplification techniques or antigen SARS-CoV-2 antigen using an immunochromatographic assay at the time of screening; 3. Severe general intoxication syndrome (severe agitation with seizure syndrome and loss of consciousness against a background of hyperthermia); 4. Hemorrhagic syndrome (nasal bleeding, blood in sputum, vomit and stool, hemorrhagic rash), disseminated intravascular coagulation syndrome (DIC) or Hasser syndrome with the formation of acute renal failure; 5. Diffuse cyanosis or pallor; 6. Symptoms of pneumonia and possible acute respiratory distress syndrome (ARDS): cough with frothy sputum with blood, shortened pulmonary sound on percussion, a large number of different-caliber moist rales and abundant crepitation on auscultation, a sharp drop in blood pressure (BP), deafness of heart tones and arrhythmia; 7. Phenomena of respiratory distress combined with any of the following symptoms: grunting breathing, blowing of the wings of the nose when breathing, nodding movements (head movements synchronized with breathing); BPM in a child aged 6-11 months > 50 per minute, child over 1 year old > 40 per minute; lower chest retraction when breathing; blood oxygen saturation (SpO2) < 92% when breathing room air; 8. Moderate acute respiratory infections (fever = 38.5 °C) with exacerbation of comorbidities; 9. Presence of any of the following symptoms: inability to drink/breastfeed; drowsiness or unconsciousness; respiratory rate less than 30 per minute or apnea; heart failure phenomena; severe dehydration; 10. Febrile seizures, including a history of seizures; known intolerance to the active ingredient or excipient of the study drug or placebo components, paracetamol; 12. Lactose intolerance, lactase deficiency or glucose-galactose malabsorption. 13. Taking antibiotics, antivirals, or immunomodulatory drugs within < 48 h prior to the study and/or plans to use these groups of drugs (other than the study drug) during the study; 14. Use of systemic, inhaled, or nasal glucocorticosteroids within 30 days prior to the study and/or plans to use glucocorticosteroids (except topical cutaneous agents) during the study; 15. Failure to withdraw for the duration of the study other medications that may affect the outcome of this study, such as antiviral medications, or medications that are incompatible with the study therapy (see "prohibited concomitant therapies"); 16. Patient's participation in any other clinical trial within 90 days prior to inclusion in the study; 17. Any cardiovascular, renal, hepatic, gastrointestinal (GI), endocrine, or nervous system disease, severe decompensated chronic or acute disease, or any other condition/disease that, in the opinion of the investigating physician, would make it unsafe for the patient to participate in the study; 18. Having any vaccinations administered to the patient within 14 days prior to inclusion in the study; 19. Diabetes mellitus; 20. Clinical suspicion of pneumonia or other bacterial infections (including sinusitis, otitis media, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibacterial drugs; 21. Patients who have had surgery within 30 days prior to the Screening Visit and patients who are scheduled to have surgery, including diagnostic procedures, or a hospital stay during the study; 22. Suspicion of hemophagocytic syndrome; 23. Increased seizure activity in the history; 24. The presence of cancer, HIV infection, tuberculosis, including in the anamnesis; 25. Suspected low compliance of the parent/adopter with the child's treatment and recording of required parameters in the Patient Diary, or inability to perform these procedures and comply with restrictions according to the study protocol (e.g., due to mental illness). Withdrawal Criteria: 1. Identification of a probable or confirmed case COVID-19; 2. Signs of complications of viral infection, including signs of secondary bacterial infection; 3. The investigating physician decides that the patient must be excluded for the patient's own benefit; 4. Withdrawal of informed consent by the parent or adoptive parent; 5. Individual intolerance to the study drug; 6. Development of NS requiring withdrawal of study drug/placebo; 7. Erroneous inclusion (for example, the patient was included in violation of the inclusion/inclusion criteria of the protocol); 8. Patient receives/needs additional treatment that may affect study outcome or patient safety (see "prohibited concomitant therapies"); 9. Persistence of nasal congestion longer than 10 days, worsening of condition after the first week of illness, facial pain; 10. Patient's development of the conditions described in the criteria for exclusion; 11. Development of hemorrhagic syndrome (including DIC): nosebleed, hemorrhagic rash on the face, neck, chest, and upper extremities, hemorrhages into the mucous membrane of the mouth and nose, the back of the throat, conjunctivae, blood in vomit, hemoptysis, etc.); 12. A pronounced intoxication syndrome with the development of encephalic or meningoencephalic reactions (delirium, hallucinations, seizures, confusion or loss of consciousness, vomiting); 13. Hemophagocytic syndrome; 14. Other conditions or events that, in the opinion of the investigating physician, require exclusion of the patient from the study.

Study Design


Intervention

Drug:
Ingavirin®, syrup, 30 mg/5 ml
A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
Placebo
Placebo will be administered once a day on top of standard therapy.

Locations

Country Name City State
Russian Federation Federal Research and Clinical Center of Physical and Chemical Medicine of the Federal Medical and Biological Agency Odintsovo Moscow Region
Russian Federation City Pediatric Outpatient Clinic number 5 Perm
Russian Federation Professors' Clinic LLC. Perm
Russian Federation City Polyclinic No. 45 of Nevsky District Saint Petersburg
Russian Federation PiterKlinika LLC Saint Petersburg
Russian Federation St. Petersburg State Budgetary Healthcare Institution "Children's City Polyclinic No. 44" Saint Petersburg
Russian Federation Uromed LLC Smolensk
Russian Federation Bashkir State Medical University Ufa

Sponsors (1)

Lead Sponsor Collaborator
Valenta Pharm JSC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time of symptoms/events resolution Time, in hours, from the first administration of the drug until all of the following symptoms/events have resolved (if each symptom/event has been achieved for at least 24 hours): Fever; Cough and/or runny nose/nasal congestion; Child's return to normal daytime activity and normal nighttime sleep (as assessed by the parent/adopter). From Day 1 up to Day 13-14 (visit 4)
Secondary Time to fever relief Number of hours elapsed from the first administration of the medication to the time of persistent normalization of the temperature, i.e., the moment when the body temperature is < 37.5 °C during the day without the use of antipyretic medication From Day 1 up to Day 13-14 (visit 4)
Secondary Time to cough relief Number of hours from the first dose to the time the coughing cough has gone away, i.e. the parent/adoptive parent rates the symptom as 0-1 during the day and records this in the patient's diary From Day 1 up to Day 13-14 (visit 4)
Secondary Time to cough/nasal congestion relief Number of hours from first medication administration to cough/congestion cessation, i.e., when parent/adopter rates severity of this symptom during the day at 0-1 point and records this in patient diary From Day 1 up to Day 13-14 (visit 4)
Secondary Frequency of complications of acute viral infection and influenza Acute otitis media, viral and bacterial pneumonia, exacerbation of chronic conditions such as bronchial asthma and urinary tract infections), toxemia [septic-like syndrome], acute stenotic laryngotracheitis From Day 1 up to Day 13-14 (visit 4)
Secondary Frequency of patients with PCR-confirmed viral infection PCR-confirmed acute respiratory infections/flu by visits 1, 2, 3 Day 1, Day 3-4 (visit 2), Day 6-7 (visit 3)
Secondary Need for paracetamol or ibuprofen Daily dose on study days 1-7 Days 1-7
Secondary Safety - Number of adverse events (AEs) Total number of AEs stratified by severity and frequency From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Adverse reactions Frequency of adverse reactions From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Serious adverse events (SAEs) Frequency of serious adverse events (SAEs) associated with study drug/placebo use From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Percentage of patients with AEs Percentage of patients with at least one AE From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Percentage of patients who interrupted treatment Percentage of patients who interrupted treatment due to AE From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Frequency of complications Frequency of complications From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Frequency of worsening Frequency of worsening of the disease course From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Secondary Safety - Frequency of hospitalization Frequency of need for hospitalization From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
See also
  Status Clinical Trial Phase
Completed NCT03275389 - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years Phase 1
Completed NCT03442582 - Afluria Pregnancy Registry
Completed NCT05981846 - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 Phase 2
Completed NCT05044195 - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age Phase 3
Completed NCT02914275 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. Phase 3
Completed NCT04590066 - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy N/A
Recruiting NCT03778203 - Development of Childhood Anti-influenza Immunity Phase 4
Completed NCT04527614 - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection N/A
Terminated NCT03658629 - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults Phase 2
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Withdrawn NCT02883972 - Childhood Influenza Immunisation Invitation Trial in Schools N/A
Completed NCT02998996 - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU Phase 1/Phase 2
Completed NCT02867358 - A Clinical Trial of KT07 Capsule in the U.S.A Phase 2
Completed NCT02545543 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age Phase 3
Completed NCT02212106 - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years Phase 4
Completed NCT02243774 - Mail Outreach To Increase Vaccination Acceptance Through Engagement N/A
Completed NCT02621164 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents Phase 3
Completed NCT02344134 - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects Phase 3
Completed NCT01674205 - Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines Phase 1